Skip to main content

Advertisement

SpringerLink
Log in

Melanoma of the head and neck

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Staging of cutaneous melanoma has changed in recent years with an increased emphasis upon thickness and ulceration on prognosis of early stage disease. Cutaneous melanoma of the head and neck is treated with complete surgical resection in early stage disease. Resection margins are determined by the size, depth, and presence of satellite lesions. Evaluation for regional and distant metastatic disease is necessary in all cases of advanced stage disease. Sentinel lymph node biopsy and possible parotidectomy and neck dissection should be considered in head and neck cutaneous melanomas greater than 1 mm in thickness or with ulceration. Adjuvant therapy may be indicated in advanced primary, nodal, and metastatic disease. Mucosal melanoma of the head and neck remains a difficult disease to treat, with high locoregional recurrence rates and poor prognosis despite aggressive therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics. CA Cancer J Clin 2004, 54:8–29.

    PubMed  Google Scholar 

  2. Greene FL, Page DL, Fleming ID, et al.: Cancer Staging Handbook. 6th ed. New York: Springer-Verlag; 2002.

    Google Scholar 

  3. Balch CM, et al.: An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004. 54(3):131–149; quiz 182–184. An extensive and detailed review of prognostic factors involved in staging patients with cutaneous melanoma provides the reader with background on the evidence behind the new staging system for melanoma.

    PubMed  Google Scholar 

  4. Balch CM, et al.: Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19(16):3622–3634. The evidence supporting the prognostic correlation of staging and clinicopathologic parameters is presented.

    PubMed  CAS  Google Scholar 

  5. Bulliard JL: Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int J Cancer 2000, 85:627–632.

    Article  PubMed  CAS  Google Scholar 

  6. Naldi L, Lorenzo Imberti G, Parazzini F, et al.:Pigmentary traits, modalities of sun reaction, history of sunburns, and melanocytic nevi as risk factors for cutaneous malignant melanoma in the Italian population: results of a collaborative case-control study. Cancer 2000, 88:2703–2710.

    Article  PubMed  CAS  Google Scholar 

  7. Rafnsson V, Hrafnkelsson J, Tulinius H, et al.: Risk factors for malignant melanoma in an Icelandic population sample. Prev Med 2004, 39:247–252.

    Article  PubMed  Google Scholar 

  8. Bakos L, Wagner M, Bakos RM, et al.:Sunburn, sunscreens, and phenotypes: some risk factors for cutaneous melanoma in southern Brazil. Int J Dermatol 2002, 41:557–562.

    Article  PubMed  Google Scholar 

  9. Fargnoli MC, Piccolo D, Altobelli E, et al.: Constitutional and environmental risk factors for cutaneous melanoma in an Italian population. A case-control study. Melanoma Res 2004, 14:151–157.

    Article  PubMed  Google Scholar 

  10. Youl P, Aitken J, Hayward N, et al.: Melanoma in adolescents: a case-control study of risk factors in Queensland, Australia. Int J Cancer 2002, 98:92–98.

    Article  PubMed  CAS  Google Scholar 

  11. Bulliard JL, Cox B, Semenciw R: Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969–93. Cancer Causes Control 1999, 10:407–416.

    Article  PubMed  CAS  Google Scholar 

  12. Nashan D, Kocer B, Schiller M, et al.: Significant risk of a second melanoma in patients with a history of melanoma but no further predisposing factors. Dermatology 2003, 206:76–77.

    Article  PubMed  Google Scholar 

  13. Hussein MR: Genetic pathways to melanoma tumorigenesis. J Clin Pathol 2004, 57:797–801.

    Article  PubMed  CAS  Google Scholar 

  14. Gillgren P, Brattstrom G, Frisell J, et al.: Body site of cutaneous malignant melanoma--a study on patients with hereditary and multiple sporadic tumours. Melanoma Res 2003, 13:279–286.

    Article  PubMed  CAS  Google Scholar 

  15. Hansen CB, Wadge LM, Lowstuter K, et al.: Clinical germline genetic testing for melanoma. Lancet 2004, 5:314–319.

    Article  CAS  Google Scholar 

  16. Hemo Y, Gutman M, Klausner JM: Anatomic site of primary melanoma is associated with depth of invasion. Arch Surg 1999, 134:148–150.

    Article  PubMed  CAS  Google Scholar 

  17. Morton DL, Hsueh EC, Essner R, et al.: Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002, 236:438–448.

    Article  PubMed  Google Scholar 

  18. Andersson AP, Gottlieb J, Drzewiecki KT, et al.: Skin melanoma of the head and neck. Prognostic factors and recurrence-free survival in 512 patients. Cancer 1992, 69:1153–1156.

    Article  PubMed  CAS  Google Scholar 

  19. Cascinelli N, Santinami M, Maurichi A, et al.: World Health Organization experience in the treatment of melanoma. Surg Clin North Am 2003, 83:405–416.

    Article  PubMed  Google Scholar 

  20. Bienert TN, Trotter MJ, Arlette JP: Treatment of cutaneous melanoma of the face by Mohs micrographic surgery. J Cutan Med Surg 2003, 7:25–30.

    Article  PubMed  Google Scholar 

  21. Cascinelli N: Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998, 14:272–275.

    Article  PubMed  CAS  Google Scholar 

  22. Piepkorn M: Melanoma resection margin recommendations, unconventionally based on available facts. Semin Diagn Pathol 1998, 15:230–234.

    PubMed  CAS  Google Scholar 

  23. Pathak I, O’Brien CJ, Petersen-Schaeffer K, et al.: Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern? Head Neck 2001, 23:785–790.

    Article  PubMed  CAS  Google Scholar 

  24. Gershenwald JE, Thompson W, Mansfield PF, et al.: Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999, 17:976–983.

    PubMed  CAS  Google Scholar 

  25. Medina-Franco H, Beenken SW, Heslin MJ, Urist MM: Sentinel node biopsy for cutaneous melanoma in the head and neck. Ann Surg Oncol 2001, 8:716–719.

    Article  PubMed  CAS  Google Scholar 

  26. O’Brien CJ, Coates AS, Petersen-Schaefer K, et al.: Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg 1991, 162:310–314.

    Article  PubMed  CAS  Google Scholar 

  27. Smithers BM, McLeod GR, Little JH: Desmoplastic melanoma: patterns of recurrence. World J Surg 1992, 16:186–190.

    Article  PubMed  CAS  Google Scholar 

  28. Byers RM: The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck. Arch Surg 1986, 121:1338–1341.

    Article  PubMed  CAS  Google Scholar 

  29. Bonnen MD, Ballo MT, Myers JN, et al.: Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 2004, 100:383–389.

    Article  PubMed  Google Scholar 

  30. Ang KK, Peters LJ, Weber RS, et al.: Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994, 30:795–798.

    PubMed  CAS  Google Scholar 

  31. Ballo MT, Ang KK: Radiation therapy for malignant melanoma. Surg Clin North Am 2003, 83:323–342.

    Article  PubMed  Google Scholar 

  32. Pidhorecky I, Lee RJ, Proulx G, et al.: Risk factors for nodal recurrence after lymphadenectomy for melanoma. Ann Surg Oncol 2001, 8:109–115.

    Article  PubMed  CAS  Google Scholar 

  33. O’Brien CJ, Petersen-Schaefer K, Stevens GN, et al.: Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997, 19:589–594.

    Article  PubMed  CAS  Google Scholar 

  34. Harwood AR: Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. Int J Radiat Oncol Biol Phys 1983, 9:1019–1021.

    PubMed  CAS  Google Scholar 

  35. Ballo MT, Bonnen MD, Garden AS, et al.: Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 2003, 97:1789–1796.

    Article  PubMed  Google Scholar 

  36. Storper IS, Lee SP, Abemayor E, Juillard G: The role of radiation therapy in the treatment of head and neck cutaneous melanoma. Am J Otolaryngol 1993, 14:426–431.

    Article  PubMed  CAS  Google Scholar 

  37. Cooper JS, Chang WS, Oratz R, et al.: Elective radiation therapy for high-risk malignant melanomas. Cancer 2001, 7:498–502.

    CAS  Google Scholar 

  38. Veness: Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (non-parotid): a better outcome with surgery and adjuvant radiotherapy. Laryngoscope 2003, 113:1827–1833.

  39. Lee RJ, Gibbs JF, Proulx GM, et al.: Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000, 46:467–474.

    Article  PubMed  CAS  Google Scholar 

  40. Rofstad EK: Radiation sensitivity in vitro of primary tumors and metastatic lesions of malignant melanoma. Cancer Res 1992, 52:4453–4457.

    PubMed  CAS  Google Scholar 

  41. Konefal JB, Emami B, Pilepich MV: Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology 1987, 164:607–610.

    PubMed  CAS  Google Scholar 

  42. Overgaard J, Overgaard M, Hansen PV, von der Maase H, et al.: Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 1986, 5:183–192.

    Article  PubMed  CAS  Google Scholar 

  43. Pyrhonen SO, Kajanti MJ: The use of large fractions in radiotherapy for malignant melanoma. Radiother Oncol 1992, 24:195–197.

    Article  PubMed  CAS  Google Scholar 

  44. Strauss A, Dritschilo A, Nathanson L, Piro AJ, et al.: Radiation therapy of malignant melanomas: an evaluation of clinically used fractionation schemes. Cancer 1981, 47:1262–1266.

    Article  PubMed  CAS  Google Scholar 

  45. Sause WT, Cooper JS, Rush S, et al.: Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991, 20:429–432.

    PubMed  CAS  Google Scholar 

  46. Mori Y, Kondziolka D, Flickinger JC, et al.: Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys 1998, 42:581–589.

    Article  PubMed  CAS  Google Scholar 

  47. Mansfield PF, Lee JE, Balch CM: Cutaneous melanoma: current practice and surgical controversies. Curr Probl Surg 1994, 31:253–374.

    Article  PubMed  CAS  Google Scholar 

  48. Burmeister BH, Smithers BM, Davis S, et al.: Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity. ANZ J Surg 2002, 72:344–348.

    Article  PubMed  CAS  Google Scholar 

  49. Agarwala SS, Kirkwood JM, Gore M, et al.: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004, 22:2101–2107.

    Article  PubMed  CAS  Google Scholar 

  50. Awada A, Gil T, Sales F, Dubuisson M, et al.: Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anti-cancer Drugs 2004, 15:499–502.

    Article  PubMed  CAS  Google Scholar 

  51. Danson S, Lorigan P, Arance A, et al.: Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003, 21:2551–2557.

    Article  PubMed  CAS  Google Scholar 

  52. de Gast GC, Batchelor D, Kersten MJ, et al.: Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN-α in patients with metastatic melanoma. Br J Cancer 2003, 88:175–180.

    Article  PubMed  CAS  Google Scholar 

  53. Hwu WJ, Krown SE, Menell JH, etx al.: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003, 21:3351–3356.

    Article  PubMed  CAS  Google Scholar 

  54. Richtig E, Hofmann-Wellenhof R, Pehamberger H, et al.: Temozolomide and interferon-α 2b in metastatic melanoma stage IV. Br J Dermatol 2004, 151:91–98.

    Article  PubMed  CAS  Google Scholar 

  55. Ridolfi R, Romanini A, Sileni VC, et al.: Temozolomide and interferon-α in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma Res 2004, 14:295–299.

    Article  PubMed  CAS  Google Scholar 

  56. Agarwala, S.S. and J.M. Kirkwood (1996). Interferons in melanoma. Curr Opin Oncol 8:167–174.

    PubMed  CAS  Google Scholar 

  57. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14:7–17.

    PubMed  CAS  Google Scholar 

  58. Vlock DR, Andersen J, Kalish LA, et al.: Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol 1996, 19:433–442.

    PubMed  CAS  Google Scholar 

  59. Shaw: Adjuvant immunotherapy for patients with melanoma: are patients with melanoma of the head and neck candidates for this therapy? Head Neck 1996, 19:595–603.

    Article  Google Scholar 

  60. Agarwala: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002, 20:125–133.

    Article  PubMed  CAS  Google Scholar 

  61. Atkins MB, Gollob JA, Sosman JA, et al.: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-α 2B in patients with metastatic melanoma. Clin Cancer Res 2002, 8:3075–3081.

    PubMed  CAS  Google Scholar 

  62. Radny P, Caroli UM, Bauer J, et al.: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003, 89:1620–1626.

    Article  PubMed  CAS  Google Scholar 

  63. Dillman RO, Soori G, Wiemann MC, et al.: Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-α, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11. Cancer Biother Radiopharm 2000, 15:487–494.

    Article  Google Scholar 

  64. Keilholz U, Stoter G, Punt CJ, et al.: Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am 1997, 3(Suppl 1):S22–28.

    PubMed  Google Scholar 

  65. Signore A, Annovazzi A, Barone R, et al.: 99mTc-Interleukin-2 Scintigraphy as a Potential Tool for Evaluating Tumor-Infiltrating Lymphocytes in Melanoma Lesions: A Validation Study. J Nucl Med 2004, 45:1647–1652.

    PubMed  Google Scholar 

  66. Vilella R, Benitez D, Mila J, et al.: Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine. Int J Cancer 2003, 106:626–631.

    Article  PubMed  CAS  Google Scholar 

  67. Berd D, Sato T, Maguire HC Jr, et al.: Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004, 22:403–415.

    Article  PubMed  CAS  Google Scholar 

  68. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al.: Doubleblind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001, 7:1882–1887.

    PubMed  CAS  Google Scholar 

  69. Reichle A, Bross K, Vogt T, et al.: Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer, 2004. Epub ahead of print.

  70. American Joint Committee on Cancer Staging Handbook TNM Classification of Malignant Tumors, 6 edn. Edited by Greene FL, Balch CM, Fleming ID, et al. New York: Springer, 2002:37.

Download references

Author information

Authors and Affiliations

  1. Head and Neck Tumor Program, Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, 29425, Charleston, SC, USA

    Terry A. Day MD,FACS

Authors
  1. Terry A. Day MD,FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joshua D. Hornig MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anand K. Sharma MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frank Brescia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Boyd Gillespie MD,FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Deanne Lathers PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Day, T.A., Hornig, J.D., Sharma, A.K. et al. Melanoma of the head and neck. Curr. Treat. Options in Oncol. 6, 19–30 (2005). https://doi.org/10.1007/s11864-005-0010-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-005-0010-5

Keywords

Search

Navigation